KR20230005210A - 스플라이싱을 조절하기 위한 화합물 및 방법 - Google Patents

스플라이싱을 조절하기 위한 화합물 및 방법 Download PDF

Info

Publication number
KR20230005210A
KR20230005210A KR1020227039044A KR20227039044A KR20230005210A KR 20230005210 A KR20230005210 A KR 20230005210A KR 1020227039044 A KR1020227039044 A KR 1020227039044A KR 20227039044 A KR20227039044 A KR 20227039044A KR 20230005210 A KR20230005210 A KR 20230005210A
Authority
KR
South Korea
Prior art keywords
compound
heterocyclyl
heteroaryl
formula
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039044A
Other languages
English (en)
Korean (ko)
Inventor
도미닉 레이놀즈
서지 레저
마이클 더블유. 세일러
아난트 에이. 아그라왈
프레데릭 베일란코트
피터 스미스
수디프 프라자파티
Original Assignee
레믹스 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레믹스 테라퓨틱스 인크. filed Critical 레믹스 테라퓨틱스 인크.
Publication of KR20230005210A publication Critical patent/KR20230005210A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
KR1020227039044A 2020-04-08 2021-04-08 스플라이싱을 조절하기 위한 화합물 및 방법 Pending KR20230005210A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063007327P 2020-04-08 2020-04-08
US63/007,327 2020-04-08
US202063043920P 2020-06-25 2020-06-25
US63/043,920 2020-06-25
US202063072873P 2020-08-31 2020-08-31
US63/072,873 2020-08-31
US202063126493P 2020-12-16 2020-12-16
US63/126,493 2020-12-16
PCT/US2021/026477 WO2021207550A1 (en) 2020-04-08 2021-04-08 Compounds and methods for modulating splicing

Publications (1)

Publication Number Publication Date
KR20230005210A true KR20230005210A (ko) 2023-01-09

Family

ID=75747105

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227039044A Pending KR20230005210A (ko) 2020-04-08 2021-04-08 스플라이싱을 조절하기 위한 화합물 및 방법
KR1020227039049A Pending KR20230004575A (ko) 2020-04-08 2021-04-08 스플라이싱을 조절하기 위한 화합물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227039049A Pending KR20230004575A (ko) 2020-04-08 2021-04-08 스플라이싱을 조절하기 위한 화합물 및 방법

Country Status (14)

Country Link
US (2) US20240287097A1 (https=)
EP (2) EP4132935A1 (https=)
JP (2) JP2023520925A (https=)
KR (2) KR20230005210A (https=)
CN (2) CN116134036A (https=)
AU (2) AU2021253571A1 (https=)
BR (2) BR112022020337A2 (https=)
CA (2) CA3175205A1 (https=)
CL (1) CL2022002779A1 (https=)
CO (1) CO2022015926A2 (https=)
CR (1) CR20220567A (https=)
IL (1) IL297149A (https=)
MX (2) MX2022012676A (https=)
WO (2) WO2021207550A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
BR112022023025A2 (pt) 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
WO2022194802A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiadiazolopyrimidone derivatives
BR112023018466A2 (pt) * 2021-03-17 2023-10-10 Hoffmann La Roche Derivados de tiazolopirimidinona
CN116997555A (zh) * 2021-03-17 2023-11-03 豪夫迈·罗氏有限公司 新颖噻吩并嘧啶酮衍生物
WO2023064879A1 (en) * 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
AU2022398247A1 (en) * 2021-11-24 2024-06-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CN115112899B (zh) * 2022-06-15 2024-08-16 四川大学华西医院 检测羧肽酶a4的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB242502A (en) * 1925-03-10 1925-11-12 Hoe & Co R Improvements in stapling and folding mechanism
JPS57142989A (en) * 1981-02-27 1982-09-03 Dai Ichi Seiyaku Co Ltd Thiazolopyrimidine derivative
JPS58177997A (ja) * 1982-04-12 1983-10-18 Dai Ichi Seiyaku Co Ltd チアジアゾロピリミジノン誘導体
DE3763282D1 (de) * 1986-03-19 1990-07-26 Kumiai Chemical Industry Co Fungizide zur verwendung in der landwirtschaft und im gartenbau.
TW449600B (en) * 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US6153614A (en) * 1998-07-16 2000-11-28 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
AR038118A1 (es) * 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US20060194871A1 (en) * 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
US20050176738A1 (en) * 2003-11-07 2005-08-11 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
KR100846988B1 (ko) * 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
WO2008057601A2 (en) * 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
CA2805724A1 (en) * 2010-07-16 2012-01-19 Rockefeller University Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
EP2721036B1 (en) * 2011-06-15 2015-07-22 Takeda GmbH Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2804610B1 (en) * 2012-01-16 2018-10-31 The Rockefeller University Organic compounds
DK2812004T3 (en) 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CA2946702C (en) * 2014-04-23 2022-06-28 Mitsubishi Tanabe Pharma Corporation Bicyclic or tricyclic heterocyclic compound
SI3143025T1 (sl) * 2014-05-15 2020-01-31 F. Hoffmann-La Roche Ag Spojine za zdravljenje spinalne mišične atrofije
US10294243B2 (en) * 2014-06-05 2019-05-21 Bayer Cropscience Aktiengesellschaft Bicyclic compounds as pesticides
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
JP6791717B2 (ja) * 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
AR106472A1 (es) * 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
CA3037642A1 (en) * 2016-09-23 2018-03-29 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200057071A (ko) 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
CA3094988A1 (en) * 2018-03-30 2019-10-03 Biotheryx, Inc. Thienopyrimidinone compounds
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
BR112023018466A2 (pt) * 2021-03-17 2023-10-10 Hoffmann La Roche Derivados de tiazolopirimidinona
WO2022194802A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiadiazolopyrimidone derivatives

Also Published As

Publication number Publication date
JP2023520925A (ja) 2023-05-22
EP4132936A1 (en) 2023-02-15
CR20220567A (es) 2023-01-13
EP4132935A1 (en) 2023-02-15
CA3175193A1 (en) 2021-10-14
JP2023520924A (ja) 2023-05-22
CL2022002779A1 (es) 2023-04-28
AU2021251220A1 (en) 2022-11-03
BR112022020418A2 (pt) 2023-05-02
BR112022020337A2 (pt) 2022-12-13
CO2022015926A2 (es) 2022-11-29
JP7797407B2 (ja) 2026-01-13
WO2021207550A1 (en) 2021-10-14
IL297149A (en) 2022-12-01
WO2021207530A8 (en) 2021-12-02
WO2021207530A1 (en) 2021-10-14
MX2022012676A (es) 2023-01-11
US20240287097A1 (en) 2024-08-29
AU2021253571A1 (en) 2022-11-10
MX2022012677A (es) 2023-01-11
KR20230004575A (ko) 2023-01-06
US20240279239A1 (en) 2024-08-22
CA3175205A1 (en) 2021-10-14
CN116134036A (zh) 2023-05-16
CN116096725A (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
JP7797407B2 (ja) スプライシングを調節するための化合物及び方法
JP7847852B2 (ja) スプライシングを調節するための化合物及び方法
TWI912305B (zh) 調節剪接之化合物及方法
KR20220157407A (ko) 핵산 스플라이싱을 조절하기 위한 피리다진 유도체
KR20220158237A (ko) 스플라이싱을 조절하기 위한 화합물 및 방법
IL299543A (en) 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
EP4416156A1 (en) Compounds and methods for modulating nucleic acid splicing
IL311132A (en) Splicing Modulation Compounds and Methods
KR20230118067A (ko) 5-[5-(피페리딘-4-일)티에노[3,2-c]피라졸-2-일]인다졸 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물
WO2024259017A1 (en) Compounds and methods for modulating splicing
KR20260047325A (ko) 스플라이싱을 조절하기 위한 화합물 및 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902